MK-0646 IGF-1R antibody combination with pemetrexed/cisplatin to be assessed for advanced non-squamous lung cancer efficacy and safety.
MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer
Abstract
A study will compare MK-0646 plus pemetrexed/cisplatin against chemotherapy alone for efficacy and safety in advanced non-squamous lung cancer.